drugset / Trial / NCT03868969

Clinical Efficacy of Fosfomycin Trometamol Per os in the Treatment of Documented Male Urinary Tract Infections With ESBL-producing Enterobacteriaceae With ESBL Producing Enterobacteriaceae and Resistance Associated With Fluoroquinolones and Cotrimoxazole (FOSF'HOM)

NCT03868969

Phase 2 Unknown 25 enrolled Centre Hospitalier Universitaire de Besancon
NaSingle-groupOpen-labelTreatment

Summary

The aim of the study was to evaluate the clinical and microbiological efficacy of fosfomycin trometamol (FT) per os in the treatment of documented male urinary tract infections with ESBL-producing enterobacteriaceae

Timeline

Start
2019-04
Primary completion
2021-04
Completion
2021-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Fosfomycin Small molecule Oral